Medios sees highest filings and grants during May in Q2 2024

Medios has been focused on protecting inventions in South Korea(KR) with one publication in Q2 2024

The South Korea(KR) Patent Office dominates the patent filings with nearly 100% of filings. The South Korea(KR) patent Office are among the top ten patent offices where Medios is filings its patents..

Johnson & Johnson and Alcon could be the strongest competitors for Medios

For comprehensive analysis of Medios’s filings and grants, buy the databook here.

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.

Do stroke and hypertension mediate associations between exposure to air pollutants and dementia?

Whether stroke or hypertension modifies or mediates the relationship between particulate matter exposure and dementia.

September 25, 2023

D3L-001 by D3 Bio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 4, 2023

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 – Biotech Investments

Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 13-Nov-2024 /

November 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.